Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Subcutaneous Pembrolizumab Coformulated with Hyaluronidase (MK-3475A) in Relapsed/Refractory cHL or PMBCL
2024-510969-42-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, single-arm trial of pembrolizumab in classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Merck & Co. Primary endpoints: Cmax of pembrolizumab after first SC MK-3475A administration, Ctrough of pembrolizumab after first SC MK-3475A administration and 2 more. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on 2024-510969-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510969-42-00.